Physiological and neurophysiological determinants of postcancer fatigue: design of a randomized controlled trial. by Prinsen, H. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
STUDY PROTOCOL Open Access
Physiological and neurophysiological
determinants of postcancer fatigue: design of a
randomized controlled trial
Hetty Prinsen1*, Gijs Bleijenberg2, Machiel J Zwarts3, Maria T.E. Hopman4, Arend Heerschap5 and
Hanneke W M van Laarhoven1,6
Abstract
Background: Postcancer fatigue is a frequently occurring, severe, and invalidating problem, impairing quality of life.
Although it is possible to effectively treat postcancer fatigue with cognitive behaviour therapy, the nature of the
underlying (neuro)physiology of postcancer fatigue remains unclear. Physiological aspects of fatigue include
peripheral fatigue, originating in muscle or the neuromuscular junction; central fatigue, originating in nerves, spinal
cord, and brain; and physical deconditioning, resulting from a decreased cardiopulmonary function. Studies on
physiological aspects of postcancer fatigue mainly concentrate on deconditioning. Peripheral and central fatigue
and brain morphology and function have been studied for patients with fatigue in the context of chronic fatigue
syndrome and neuromuscular diseases and show several characteristic differences with healthy controls.
Methods/design: Fifty seven severely fatigued and 21 non-fatigued cancer survivors will be recruited from the
Radboud University Nijmegen Medical Centre. Participants should have completed treatment of a malignant, solid
tumour minimal one year earlier and should have no evidence of disease recurrence. Severely fatigued patients are
randomly assigned to either the intervention condition (cognitive behaviour therapy) or the waiting list condition
(start cognitive behaviour therapy after 6 months). All participants are assessed at baseline and the severely fatigued
patients also after 6 months follow-up (at the end of cognitive behaviour therapy or waiting list). Primary outcome
measures are fatigue severity, central and peripheral fatigue, brain morphology and function, and physical condition
and activity.
Discussion: This study will be the first randomized controlled trial that characterizes (neuro)physiological factors of
fatigue in disease-free cancer survivors and evaluates to which extent these factors can be influenced by cognitive
behaviour therapy. The results of this study are not only essential for a theoretical understanding of this invalidating
condition, but also for providing an objective biological marker for fatigue that could support the diagnosis and
follow-up of treatment.
Trial registration: The study is registered at ClinicalTrials.gov (NCT01096641).
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Brain metabolism, Physical condition, Physical activity
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Postcancer fatigue (PCF) is a frequently occurring, se-
vere, and invalidating problem in cancer survivors,
impairing quality of life.[1,2] About 70 to 96% of the
cancer patients undergoing chemotherapy and/or radio-
therapy experience symptoms of fatigue.[3,4] The preva-
lence of PCF observed in longitudinal follow-up studies
ranged from 19 to 39%.[1,5-8] Previous disease and
treatment characteristics are unrelated to PCF.[2,4,9-12]
However, there is some evidence that patients who are
treated with only a surgery are less at risk for PCF[8]
and survivors who are treated with more aggressive
treatments are more at risk for PCF [1,13]. Cognitive be-
haviour therapy (CBT), especially designed for PCF,
seemed to be an effective treatment option for PCF.
[11,14] However, although it is now possible to effect-
ively treat PCF, the nature of the underlying physiology
of PCF remains unclear.
The term fatigue in the medical literature usually refers
to fatigue experienced by the patient, but it can also refer
to physiological fatigue. Fatigue experienced by the patient
and its psychological aspects can be quantified using ques-
tionnaires. Physiological aspects of fatigue include periph-
eral fatigue, originating in muscle or the neuromuscular
junction; central fatigue, originating in nerves, spinal cord,
and brain; and physical deconditioning, resulting from a
decreased cardiopulmonary function.
Peripheral and central fatigue
In physiology, fatigue is usually defined as the loss of
voluntary force-producing capacity during exercise,[15]
which can have a peripheral and a central origin.[16]
During peripheral muscle fatigue, membrane excitability
of muscle tissue is influenced due to a decrease in pH,
accumulation of lactate, and changes in intra- and extra-
cellular ion concentration.[17] Muscle fibre conduction
velocity (MFCV), which can be determined by surface
electromyography (sEMG), reflects the peripheral situ-
ation.[16] Alternatively, peripheral fatigue can be quanti-
fied by measuring the muscular force response to
artificial electrical stimulation before and after exercise.
Besides peripheral factors, a failure of drive from the
central nervous system may also contribute to fatigue
[18] This sub-maximal central activation during exercise,
or central activation failure (CAF), is named central fa-
tigue[16] and can be measured with a twitch
interpolation technique.[19]
Physiological fatigue has been studied in patients with
neuromuscular diseases,[20] in patients with chronic fa-
tigue syndrome (CFS),[21] but also in cancer patients to
evaluate cancer-related fatigue.[22] In a study of 16 can-
cer patients referred to palliative medicine and 16
matched non-cancer controls, neuromuscular testing
was applied to determine whether cancer-related fatigue
is a more centrally or peripherally mediated disorder.
[22] Patients suffering from cancer-related fatigue
showed less peripheral muscle fatigue and more central
muscle fatigue compared to their non-fatigued controls.
It should be noted that some psychological aspects of
fatigue are different for different neuromuscular diseases
[23] as well as for fatigue in CFS and for cancer-related
fatigue. Nevertheless, CAF appears to be a shared neuro-
physiological feature of fatigue in all these diseases.
Therefore, it is of great interest to know whether PCF is
also characterized by CAF.
Although CAF implies a central origin of fatigue, it is
still unclear from which part of the central nervous sys-
tem the failure originates. Therefore, further studies on
brain morphology and brain metabolism are essential to
elucidate the (neuro)physiological basis of fatigue.
Brain morphology and metabolism
Using magnetic resonance imaging (MRI), several stud-
ies have reported structural abnormalities in the brains
of patients with CFS. In a group of 259 fatigued patients,
specific hyperintense small punctuated subcortical
white-matter foci were observed.[24] Similar results have
been reported by others.[25-27] Different research
groups conducted voxel-based morphometry (VBM) in
CFS patients and matched healthy controls and observed
gray matter volume reductions in fatigued patients com-
pared to non-fatigued controls.[28,29] Interestingly, it
has been shown that CFS patients showed a significant
increase in gray matter volume, localized in the lateral
prefrontal cortex, after CBT.[30]
Magnetic resonance spectroscopy (MRS) provides a
non-invasive window on metabolism in the brain. Stud-
ies with proton (1H) MRS allow the detection and quan-
tification of metabolites like choline, creatine, N-
acetylaspartate, and lactate. Choline is a precursor of
membrane phospholipids and an elevated choline level
has been associated with increased cell membrane turn-
over, cell density, and gliosis. Choline levels vary over
the brain and the choline to creatine ratio is higher in
white matter than in gray matter. In a 1H MRS study of
the brain of CFS patients and eight age- and sex-
matched healthy control subjects, the mean ratio of cho-
line to creatine in the occipital cortex of fatigued
patients was significantly higher compared to healthy
controls.[31] The amount of creatine in the brain is
assumed to be constant. An increased choline to creat-
ine ratio suggests an abnormality of phospholipid metab-
olism and/or associated brain morphology. Similarly, in
a 1H MRS study of the left basal ganglia, a highly signifi-
cant increase in the signal from choline-containing com-
pounds was seen in CFS patients compared to age- and
sex-matched healthy controls.[32] In three children with
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CFS, 1H MRS demonstrated a significantly higher cho-
line to creatine ratio in the frontal cortex compared to
healthy controls.[33] N-acetylaspartate is considered to
be a marker of neuronal density and neuronal function.
In one study, reduced levels of N-acetylaspartate were
observed in the right hippocampus of seven CFS patients
compared to healthy controls.[34] Elevated lactate in the
brain may suggest cerebral energy dysfunction. The
presence of elevated ventricular lactate was observed in
sixteen CFS patients as compared to healthy controls.
[35]
Especially for CFS, certain characteristics of brain
morphology and metabolism may serve as objective bio-
markers for fatigue. However, since CFS and PCF differ
in some psychological aspects[36] it still needs to be
shown that these characteristics also play a role in PCF.
Physical condition and activity
Despite the fact that current cancer treatments are in-
creasingly efficacious for improving survival, they are
toxic in numerous ways. Therefore, many cancer
patients are forced to decrease their physical activity,
possibly leading to physical deconditioning. Physical ac-
tivity levels were significantly reduced after diagnosis in
a study of 812 breast cancer patients.[37] It may be
hypothesized that compared to non-fatigued cancer sur-
vivors, PCF patients have an impaired physical condition
due to decreased physical activity after cancer treatment.
In a previous study comparing physical condition in a
group of 20 CFS patients and 20 matched non-fatigued
sedentary controls, physical condition did not signifi-
cantly differ between both groups. Although as a clinical
syndrome CFS and PCF show strong similarities, in PCF
a clear precipitating moment can be identified that pro-
voked fatigue, namely the diagnosis of cancer and its
subsequent treatment. In contrast to PCF, not always a
precipitating factor can be identified in CFS. Therefore,
studies on physical condition, specifically in cancer sur-
vivors, are needed to investigate the physiology of PCF.
Methods/design
Study design
A randomized controlled trial (RCT) with 6 months
follow-up will be conducted to identify and measure
(neuro)physiological factors of fatigue in severely
fatigued disease-free cancer survivors and to deter-
mine the role of these factors in the maintaining of
fatigue. At baseline, fatigued and non-fatigued
patients will undergo measurements for peripheral
and central fatigue, brain morphology and metabol-
ism, and physical condition and activity. Fatigued
patients will be randomly assigned to either the
intervention group, who will immediately start CBT,
or the control group, who will start CBT after six
months. After six months follow-up, the measure-
ments will be repeated in both groups of fatigued
patients.
Ethical consideration
This study has been approved by the Medical Ethical
Committee of the Radboud University Nijmegen Med-
ical Centre (RUNMC). Patients will be informed about
the study and informed consent will be obtained before
randomization.
Study population
Patients who have been curatively treated for cancer and
finished treatment at least one year before, will be asked
by their physician to fill out the Checklist Individual
Strength (CIS),[38] RAND-36,[39] Beck Depression In-
ventory for Primary Care (BDI-pc),[40] and some add-
itional demographic and medical questions during their
control-visits. Based on the scores of the fatigue severity
subscale of the CIS (CIS-fatigue), patients with a cut-off
score of ≥35 will be classified as severely fatigued. Se-
verely fatigued patients, who are referred to the Expert
Centre for Chronic Fatigue of the RUNMC and who met
the in- and exclusion criteria of the study (Table 1), will
be informed by their treating psychologist about the
study. If the patients agree to be further informed about
the study, the researcher will inform the patients exten-
sively about the study and will ask for participation. Se-
verely fatigued patients will be matched with non-
fatigued patients with respect to age, sex, and previous
cancer treatment (Figure 1). A total number of 57 se-
verely fatigued and 21 non-fatigued cancer survivors will
be included (see power calculation).
Table 1 Inclusion and exclusion criteria
Inclusion
criteria
(1) Age between 19 and 65 years
(2) Age at disease onset minimal 18 years
(3) Treated for a malignant, solid tumour
(4) Completion of treatment for cancer minimal 1
year ago (single treatment modality surgery/
current hormonal therapy permitted)
(5) Disease-free, as defined by the absence of
somatic disease activity parameters
Exclusion
criteria
(1) Physical comorbidity that could explain the fatigue
(2) Current psychological or psychiatric treatment
(3) Brain tumour in the past
(4) Contra-indication for MR examinations
(e.g. claustrophobia)
(5) Treatment with anti-depressive drugs, anti-epileptic
drugs, or benzodiazepines
(6) Insufficient command of the Dutch language
to fill out questionnaires
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Randomization and intervention
As shown in Figure 1, severely fatigued patients will be
randomized to either the intervention group (75%) or
the control group (25%). Randomization will take place
per patient. Patients randomized to the intervention
group will be treated with CBT for PCF, as described
previously.[14] The treatment consists of 12–14 individ-
ual sessions in six months. Patients randomized to the
control group will be treated with CBT after six months.
Outcome measures
Peripheral and central fatigue
To obtain maximal voluntary contraction (MVC) of the
biceps brachii muscle, participants will make MVCs,
with 1 min intervals, until no further force increase was
observed. After a rest period of 10 min, peripheral and
central fatigue will be measured during a 2 min sus-
tained MVC of the biceps brachii muscle.[18] During
these 2 min, electrical endplate stimulation over the
motor points of the medial and lateral head of the biceps
brachii muscle will be applied every 15 s, leading to
superimposed force responses. Patients will be verbally
encouraged to perform maximally throughout the 2 min.
An indicator of peripheral muscle fatigue is MFCV,
which will be measured using sEMG.[16] Peripheral
muscle fatigue will also be quantified by measuring the
muscular force response to electrical endplate stimula-
tion before and after the test. An indicator of central
muscle fatigue is additional force production upon elec-
trical endplate stimulation during exercise.[18] Submaxi-
mal central activation during exercise, or CAF, will be
measured using a twitch interpolation technique.[19]
Brain morphology and metabolism
Global volumes of gray and white matter, subcortical
brain volumes, and brain metabolite concentrations will
be obtained. MR measurements will be performed on a
3 Tesla MR System using a radiofrequency head coil.
High resolution (1 mm3), T1 weighted MR images of the
whole brain will be acquired using a magnetization pre-
pared rapid acquisition gradient echo (MPRAGE) se-
quence. Normalizing, bias-correcting, and segmenting
into global volumes of gray and white matter will be per-
formed using the VBM method.[41] Automatic
21 non-fatigued patients 15 fatigued patients on 
waiting list
42 fatigued patients to be 
treated immediately
20 non-fatigued patients 14 fatigued patients on waiting list
40 patients to be treated
11 untreated patients
10 untreated patients
32 CBT treated patients
30 CBT treated patients
10 non-responding 
patients 20 responding patients
5% technical failure
14% dropout and 6% 
cancer recurrence during/ 
after CBT or waiting list
5% technical failure
70% response to CBT
Baseline 
measurements
Measurements after 6 









Figure 1 Flow-chart of the study.
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segmentation of subcortical brain structures was per-
formed using the FIRST module of FSL.[42]
1H MR spectroscopic imaging (MRSI) will be per-
formed, with special interest for the hippocampus, the oc-
cipital cortex, the frontal cortex, and the ventricles. The
1H MRSI will allow the identification and quantification of
metabolites like choline, creatine, N-acetylaspartate, and
lactate. Volume selection will be performed with a semi-
localized by adiabatic selective refocusing (semi-LASER)
pulse sequence [43] with a repetition time of 1500 ms, an
echo time of 30 or 136 ms, and a voxel size of 10 mm3.
The data will be analyzed using LCModel software.
Physical condition and activity
To measure maximal oxygen consumption (VO2max) a
maximal exercise test will be performed.[44] In addition
to the determination of VO2max, carbon dioxide pro-
duction, heart rate, respiratory quotient, and ventilation
will be measured. Patients will cycle with an increased
workload of 10 Watt/min for women and 20 Watt/min
for men. Patients will be verbally encouraged to perform
maximally until exhaustion.
Daily activity will be measured during two weeks using
an actometer.[45] The actometer used is a motion-sensing
device, worn around the ankle, which can register and
quantify human physical activity. The actometer has a
piezoelectric sensor that is sensitive in three directions.
Accelerations of the built-in sensor larger than a prede-
fined threshold are considered as activity and are stored in
an internal memory every five minutes. A general physical
activity score expressed in the average number of accelera-
tions per 5-min period will be provided for the whole
measurement period. Actometer testing is part of the
standard care if patients are referred for CBT. To assess
the effect of the maximal exercise test on the daily activity
of patients, they will wear an actometer for an additional
five days after the maximal exercise test.
Finally, participants will score their physical activity
level long before cancer diagnosis on a 10 point numeric
rating scale.
Fatigue and psychosocial measures
Fatigued severity will be measured using the CIS-fatigue
(8 items, 7-points Likert Scale, severity range from 8 to
56).[38] High scores indicate a high level of fatigue. This
questionnaire has excellent psychometric properties, in-
cluding good reliability and discriminative validity.[46]
Simultaneously to the actometer measurements, daily
observed fatigue (DOF) will be measured with the Self-
Observation List (4 times a day, 4-point scale)[47] two
weeks prior and five days subsequent to the maximal ex-
ercise test. This instrument gives the actual level of daily
fatigue. In this way, the relation between actual fatigue
levels and the (neuro)physiological measures can be
accessed directly.
To examine whether self-efficacy (SE) regarding the
maximal exercise test could be an explanation for pos-
sible discrepancies in VO2max between fatigued and
non-fatigued participants, SE regarding the maximal ex-
ercise test will be measured using a task-specific SE
questionnaire. This questionnaire consists of 9 questions
concerning sense of control (each item scored on a 4
point numeric scale, total score range from 9 to 36) and
was adapted from the self-efficacy scale (SES)[48] The
SES measures the perceived level of control over fatigue,
whereas the task-specific SE questionnaire used in this
study measures the sense of control regarding the test. A
higher score indicates a higher sense of control regard-
ing the maximal exercise test.
To assess whether environmental factors, like social sup-
port (SS) for exercise, may influence physical activity be-
haviour, SS will be investigated using the shortened van
Sonderen SS Inventory (SSL).[49] The SSL is divided into
the SSL-I (amount of SS, 8 questions, score range from 8
to 32), the SSL-D (discrepancy between the amount of SS
and the desired amount of SS, 8 questions, score range
from 0 to 32), and the SSL-N (negative interactions, un-
supportive behaviour, 7 questions, score range from 7 to
28). A higher score indicates a higher amount of SS, dis-
crepancy, or negative interactions.
Statistical analysis
Independent samples t tests will be performed testing
baseline differences in primary and secondary outcome
measures between fatigued and non-fatigued cancer sur-
vivors. Baseline differences between the therapy and
waiting list condition are entered as covariates in further
analyses. A paired t test will be performed to test
whether differences can be observed within the therapy
or waiting list condition from baseline to follow-up. Dif-
ferences between the therapy and waiting list group on
the change in outcome measures from baseline to
6 months later will be calculated with analyses of covari-
ance (ANCOVA).
Power calculation
From previous studies in patients with CFS compared to
healthy controls we know that groups of at least 10, pre-
ferably 20 patients per condition are sufficient to detect
significant differences in (neuro)physiological parameters
measured with sEMG, MRI, and exercise testing.
[21,28,50,51] To identify (neuro)physiological character-
istics of fatigue, a comparison of baseline measurements
with an age, sex, and previous cancer treatment matched
group of 20 non-fatigued patients is sufficient. Fifty
seven severely fatigued patients are needed to measure a
change in (neuro)physiological factors due to CBT. As
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depicted in Figure 1, we assume that 5% of the measure-
ments will yield technically insufficient data and 20% of
the fatigued patients will drop-out from the study (14%
drop-out due to failure to complete CBT or the follow-
up measurements and 6% due to cancer recurrence dur-
ing or after CBT or waiting list). Assuming that about
two third of the patients who complete CBT will have a
clinically significant response to CBT, defined as a CIS-
fatigue score of less than 35 points, there will be 20
responding patients, 10 non-responding patients, and 10
untreated patients. Based on 30 patients in the CBT con-
dition and 10 patients in the waiting list condition and
assuming that the success rate of CBT is about 67% and
the chance to recover spontaneously in the waiting list
condition is maximally 10%, the power of the study to
demonstrate a significantly greater decrease in CIS-
fatigue score in patients in the intervention condition
than in patients in the waiting list condition will be at
least 80%.
Discussion
To the best of our knowledge, this will be the first study
that characterizes (neuro)physiological factors of fatigue
in disease-free cancer survivors and the changes of these
factors in a randomized controlled way.
Studies on physiological aspects of PCF mainly con-
centrate on (cardiopulmonary) deconditioning. Other
aspects of fatigue, like peripheral and central fatigue and
brain morphology and function have been studied for
patients with fatigue in the context of CFS and neuro-
muscular diseases and show several characteristic differ-
ences with healthy controls. CAF appears to be a shared
neurophysiological feature of fatigue. CFS patients
showed a significant reduced gray matter volume com-
pared to healthy controls and even showed a significant
increase in gray matter volume after CBT. Altered levels
of specific metabolites in the brains of patients with
CFS, measured with 1H MRS, have been reported. CFS
patients showed a significant reduced physical activity,
measured by actigraphy, compared to healthy controls.
Therefore, further studies on (neuro)physiological
aspects of fatigue in cancer survivors are essential not
only for a theoretical understanding of this invalidating
condition, but also for providing an objective biological
marker that could support the diagnosis of fatigue and
follow-up of the treatment of fatigue.
In conclusion, the aim of this study is to identify and
measure physiological, structural, and metabolic factors
of fatigue in disease-free cancer survivors and to deter-
mine the role of these factors in the maintaining of fa-
tigue. The identification of (neuro)physiological factors
of persistent fatigue can help to improve the diagnostics
of fatigue, predict therapy outcome, and facilitate other
treatment options. Finally, if (neuro)physiological
characteristics of fatigue can be influenced by CBT, it
will enhance our understanding of the mechanism caus-
ing fatigue.
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